MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells

BACKGROUND: Chemotherapy is one of the most common treatment options for breast cancer (BC) patients. However, about half of the BC patients are chemotherapeutic resistant. Doxorubicin (DOX) is considered as one of the first line drugs in the treatment of BC patients whose function is negatively aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Zangouei, Amir Sadra, Alimardani, Maliheh, Moghbeli, Meysam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170947/
https://www.ncbi.nlm.nih.gov/pubmed/33858435
http://dx.doi.org/10.1186/s12935-021-01873-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170947/
https://www.ncbi.nlm.nih.gov/pubmed/33858435
http://dx.doi.org/10.1186/s12935-021-01873-4

Ejemplares similares